Barclays
TRIL

Barclays’s Trillium Therapeutics Inc. TRIL Stock Holding History

Barclays’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-390,496
Closed -$6.86M – 4958
2021
Q3 		$6.86M Buy
390,496
+378,119
+3,055% +$4.42M ﹤0.01% 1408
2021
Q2 		$120K Buy
12,377
+9,214
+291% +$86.7K ﹤0.01% 3780
2021
Q1 		$34K Buy
3,163
+2,966
+1,506% +$36.7K ﹤0.01% 4283
2020
Q4 		$3K Sell
197
-349,103
-100% -$5.03M ﹤0.01% 4808
2020
Q3 		$4.96M Sell
349,300
-134,939
-28% -$1.35M ﹤0.01% 1406
2020
Q2 		$3.92M Buy
484,239
+353,069
+269% +$2.18M ﹤0.01% 1555
2020
Q1 		$530K Buy
+131,170
New +$496K ﹤0.01% 3533
2018
Q1 		– Sell
-10,500
Closed -$76K – 7467
2017
Q4 		$76K Buy
+10,500
New +$87K ﹤0.01% 5459

Other funds holding TRIL

Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Barclays's TRIL Position: Q4 2021 in Review

Barclays sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 390,496 shares — an estimated $6.86M sold.

Barclays first reported a position in TRIL in Q4 2017 and held it in 8 quarters. The position peaked at $6.86M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

  • Barclays reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
  • Barclays sold 390,496 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $6.86M.
  • Barclays first reported a position in Trillium Therapeutics Inc. in Q4 2017 and held it in 8 quarters.
  • Barclays's Trillium Therapeutics Inc. position peaked at $6.86M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.